133 related articles for article (PubMed ID: 15293139)
1. Types of human leukocyte antigen and decrease in HCV core antigen in serum for predicting efficacy of interferon-Alpha in patients with chronic hepatitis C: analysis by a prospective study.
Muto H; Tanaka E; Matsumoto A; Yoshizawa K; Kiyosawa K;
J Gastroenterol; 2004 Jul; 39(7):674-80. PubMed ID: 15293139
[TBL] [Abstract][Full Text] [Related]
2. Evolution of hepatitis C virus-specific T cell responses and cytokine production in chronic hepatitis C patients treated with high doses of interferon-alpha.
Alvarado Esquivel C; Elewaut A; Philippé J; Elewaut AE; Desombere I; Maertens G; Leroux-Roels G
Rev Invest Clin; 2002; 54(1):41-50. PubMed ID: 11995406
[TBL] [Abstract][Full Text] [Related]
3. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
Chuang WL; Dai CY; Chang WY; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA.
Tanaka E; Ohue C; Aoyagi K; Yamaguchi K; Yagi S; Kiyosawa K; Alter HJ
Hepatology; 2000 Aug; 32(2):388-93. PubMed ID: 10915747
[TBL] [Abstract][Full Text] [Related]
5. Significance of serum immunoglobulin M to hepatitis C virus core in patients with chronic hepatitis C.
Tran A; Yang G; Dreyfus G; Rouquié P; Durant J; Rampal A; Rampal P; Benzaken S
Am J Gastroenterol; 1997 Oct; 92(10):1835-8. PubMed ID: 9382047
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the clinical usefulness of COBAS AMPLICOR HCV MONITOR assay (ver2.0): Comparison with AMPLICOR HCV MONITOR assay (ver1.0) and HCV core protein level.
Kawai S; Yokosuka O; Imazeki F; Saisho H; Mizuno C
J Med Virol; 2002 Nov; 68(3):343-51. PubMed ID: 12226820
[TBL] [Abstract][Full Text] [Related]
7. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of natural BALL-1 interferon-alpha treatment for patients with chronic hepatitis C and a possible enhancing effect of a twice-daily starting regimen with interferon-beta.
Ebinuma H; Saito H; Tada S; Nakamoto N; Kurita S; Kitamaura K; Horikawa H; Kumagai N; Tsuchimoto K; Ishii H; Hibi T;
Hepatogastroenterology; 2006; 53(67):94-9. PubMed ID: 16506384
[TBL] [Abstract][Full Text] [Related]
9. Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN-resistant cases with hepatocyte steatosis.
Akuta N; Suzuki F; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
J Med Virol; 2005 Apr; 75(4):550-8. PubMed ID: 15714492
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of interferon retreatment after relapse for chronic hepatitis C patients with biochemical response after first interferon therapy.
Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Suzuki F; Akuta N; Someya T; Hosaka T; Kobayashi M; Kumada H
J Gastroenterol; 2004; 39(5):455-60. PubMed ID: 15175944
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of clinical usefulness of second-generation HCV core antigen assay: comparison with COBAS AMPLICOR HCV MONITOR assay version 2.0.
Yokosuka O; Kawai S; Suzuki Y; Fukai K; Imazeki F; Kanda T; Tada M; Mikata R; Hata A; Saisho H
Liver Int; 2005 Dec; 25(6):1136-41. PubMed ID: 16343063
[TBL] [Abstract][Full Text] [Related]
12. [Serologic response against hepatitis C virus as a predictive factor to the treatment with interferon].
Garrido A; Lepe JA; Guerrero FJ; Palomo S
Enferm Infecc Microbiol Clin; 2000 Dec; 18(10):512-5. PubMed ID: 11198002
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation.
Casanovas-Taltavull T; Baliellas C; Benasco C; Serrano TT; Casanova A; Pérez JL; Guerrero L; González MT; Andres E; Gil-Vernet S; Casais LA
Am J Gastroenterol; 2001 Apr; 96(4):1170-7. PubMed ID: 11316166
[TBL] [Abstract][Full Text] [Related]
14. Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C.
Lasarte JJ; García-Granero M; López A; Casares N; García N; Civeira MP; Borrás-Cuesta F; Prieto J
Hepatology; 1998 Sep; 28(3):815-22. PubMed ID: 9731578
[TBL] [Abstract][Full Text] [Related]
15. [Treatment response in chronic hepatitis C. Content of virus in serum is decisive for the outcome].
Weiland O; Danielsson A; Lööf L
Lakartidningen; 1998 Jan; 95(1-2):40-3. PubMed ID: 9458644
[TBL] [Abstract][Full Text] [Related]
16. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.
Zografos TA; Liaskos C; Rigopoulou EI; Togousidis E; Makaritsis K; Germenis A; Dalekos GN
Am J Gastroenterol; 2008 Mar; 103(3):605-14. PubMed ID: 18190648
[TBL] [Abstract][Full Text] [Related]
17. [Effects of HCV genotypes and HLA-DRB alleles on the response of chronic hepatitis C patients to interferon alpha and libavilin].
Jiao J; Wang JB
Zhonghua Gan Zang Bing Za Zhi; 2003 Oct; 11(10):620-2. PubMed ID: 14572343
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy.
Tokita H; Fukui H; Tanaka A; Kamitsukasa H; Yagura M; Harada H; Okamoto H
J Gastroenterol Hepatol; 2005 May; 20(5):752-8. PubMed ID: 15853990
[TBL] [Abstract][Full Text] [Related]
19. Lymphoproliferative responses to hepatitis C virus core, E1, E2, and NS3 in patients with chronic hepatitis C infection treated with interferon alfa.
Leroux-Roels G; Esquivel CA; DeLeys R; Stuyver L; Elewaut A; Philippé J; Desombere I; Paradijs J; Maertens G
Hepatology; 1996 Jan; 23(1):8-16. PubMed ID: 8550052
[TBL] [Abstract][Full Text] [Related]
20. Association between human leukocyte antigen (HLA) and interferon- induced thyroid diseases in four patients with HCV-related chronic hepatitis.
Labbadia G; Martocchia A; Mammarella A; Paoletti V; Rocco A; Benvenuto R; Antonella P; Rosaria D; Trabace S; Musca A; Falaschi P
Neuro Endocrinol Lett; 2005 Apr; 26(2):109-12. PubMed ID: 15855880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
